Pharmigene, Inc. (TPEX:7595)

Market Cap	577.82M
Revenue (ttm)	116.53M
Net Income (ttm)	-82.86M
Shares Out	50.47M
EPS (ttm)	-1.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Average Volume	4,271
Open	11.45
Previous Close	11.45
Day's Range	11.45 - 11.45
52-Week Range	9.88 - 19.20
Beta	0.12
RSI	35.69
Earnings Date	Aug 8, 2025

About Pharmigene

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services. In addition, it distributes various genomics and genetics equipment and reagents; and provides professional co...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7595

Financial Performance

In 2024, Pharmigene's revenue was 116.53 million, a decrease of -12.19% compared to the previous year's 132.71 million. Losses were -82.86 million, 14.1% more than in 2023.